| Heartlinks Hospice And Pallative Care 3920 Outlook Road, Sunnyside, WA, 98944 | |
| (509) 837-1676 |
News Archive
In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks.
The use of high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess bone microarchitecture in clinical studies has continued to grow rapidly. Thus, there is an urgent need for guidance and consensus on the methods for and reporting of HR-pQCT imaging so that different studies can be compared to each other.
Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.
Melanoma rates in the United States have doubled over the past two decades.1 Fortunately for patients, this increase in melanoma incidence has been accompanied by the development of more effective tools for diagnosis and treatment, including genetic and molecular testing.
› Verified 9 days ago
| Name | Heartlinks Hospice And Pallative Care |
|---|---|
| Location | 3920 Outlook Road, Sunnyside, Washington |
| Hospice ID | 501519 |
| Category | Freestanding Hospice |
| Ownership Type | Voluntary Non-profit - Private |
| Profit Type | NON-PROFIT |
| SSA county code | 380 |
News Archive
In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks.
The use of high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess bone microarchitecture in clinical studies has continued to grow rapidly. Thus, there is an urgent need for guidance and consensus on the methods for and reporting of HR-pQCT imaging so that different studies can be compared to each other.
Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.
Melanoma rates in the United States have doubled over the past two decades.1 Fortunately for patients, this increase in melanoma incidence has been accompanied by the development of more effective tools for diagnosis and treatment, including genetic and molecular testing.
› Verified 9 days ago
| NPI Number | 1255418430 |
| Organization Name | Heartlinks |
| Address | 3920 Outlook Rd Sunnyside, Washington, 98944 |
| Phone Number | (509)837-1676 |
News Archive
In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks.
The use of high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess bone microarchitecture in clinical studies has continued to grow rapidly. Thus, there is an urgent need for guidance and consensus on the methods for and reporting of HR-pQCT imaging so that different studies can be compared to each other.
Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.
Melanoma rates in the United States have doubled over the past two decades.1 Fortunately for patients, this increase in melanoma incidence has been accompanied by the development of more effective tools for diagnosis and treatment, including genetic and molecular testing.
› Verified 9 days ago
| Quality Measure | Provider Score | National Score |
|---|---|---|
| Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 100.0 | 98.3 |
| Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 100.0 | 93.6 |
| Patients who were checked for pain at the beginning of hospice care | 100.0 | 93.9 |
| Patients who got a timely and thorough pain assessment when pain was identified as a problem | 94.0 | 77.7 |
| Patients who were checked for shortness of breath at the beginning of hospice care | 100.0 | 97.3 |
| Patients who got timely treatment for shortness of breath | 99.2 | 94.6 |
| Patients taking opioid pain medication who were offered care for constipation | 100.0 | 93.3 |
News Archive
In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks.
The use of high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess bone microarchitecture in clinical studies has continued to grow rapidly. Thus, there is an urgent need for guidance and consensus on the methods for and reporting of HR-pQCT imaging so that different studies can be compared to each other.
Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.
Melanoma rates in the United States have doubled over the past two decades.1 Fortunately for patients, this increase in melanoma incidence has been accompanied by the development of more effective tools for diagnosis and treatment, including genetic and molecular testing.
› Verified 9 days ago
| Home Health Aides | 6 |
| Licensed Practical or Vocational Nurses | 1 |
| Medical Social Workers | 2 |
| Physicians | 2 |
| Registered Nurses | 15 |
| Total Employees | 26 |
|---|
News Archive
In follow-up to the I HART CGM study, which showed the benefit of real-time continuous glucose monitoring compared to flash monitoring for time spent in hypoglycemia among adults with type 1 diabetes at high hypoglycemia risk, researchers conducted an extension trial that assessed the effects of continuing RT-CGM or switching from flash to RT-CGM of the subsequent 8 weeks.
The use of high-resolution peripheral quantitative computed tomography (HR-pQCT) to assess bone microarchitecture in clinical studies has continued to grow rapidly. Thus, there is an urgent need for guidance and consensus on the methods for and reporting of HR-pQCT imaging so that different studies can be compared to each other.
Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.
Melanoma rates in the United States have doubled over the past two decades.1 Fortunately for patients, this increase in melanoma incidence has been accompanied by the development of more effective tools for diagnosis and treatment, including genetic and molecular testing.
› Verified 9 days ago
| Heartlinks Hospice And Pallative Care Location: 3920 Outlook Road, Sunnyside, Washington, 98944 Phone: (509) 837-1676 |